Virtus Biotech Clinical Trials ETF
20 hedge funds and large institutions have $12.3M invested in Virtus Biotech Clinical Trials ETF in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Holders
20
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$1.23M | |
| 2 | +$794K | |
| 3 | +$466K | |
| 4 |
FTUS
Flow Traders U.S.
New York
|
+$425K |
| 5 |
KCP
Kera Capital Partners
San Jose,
California
|
+$180K |
Top Sellers
| 1 | -$576K | |
| 2 | -$526K | |
| 3 | -$487K | |
| 4 |
HF
HRT Financial
New York
|
-$234K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$198K |
